The Determination and Control of Genotoxic Impurities in APIs - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Determination and Control of Genotoxic Impurities in APIs
The authors provide an overview of methods for the quantitative determination of genotoxic impurities (GTIs) in active pharmaceutical ingredients.


Pharmaceutical Technology
Volume 35, pp. s24-s30

Control of selected GTIs in APIs

GTIs can be well controlled by the process, without affecting quality, by modifying the route of synthesis. Methods for controlling sulfonates and alkylating agents are described below.

Sulfonates. Sulfonate ester formation is dramatically reduced at low amounts of water, or when acid is partially neutralized by substoichiometric concentrations of the weak base, 2,6 lutidine, to mimic conversion of a basic API to a salt. In the presence of a slight excess of base, ester formation was drastically reduced. These findings, particularly those involving an excess of base, are compelling and provide a scientific understanding to allow for the design of process conditions to minimize and control sulfonate formation (19).

Alkylating agents. Effective control of the alkylation process was possible because dimethyl sulfonate reagents barely reacted with nylon at room temperature (i.e., 25 °C). At 100 °C, the reaction could be stopped rapidly by immersing the tube in an ice bath. The optimum incubation times for alkylation with dimethyl sulfonate and diethyl sulfonate were 3 and 10 min, respectively. Dimethyl sulfonate, a less toxic reagent than dimethyl sulfonate, caused less damage to the nylon tubes and produced more chemically stable O-alkylated derivatives (20).

Conclusion

Identification and control of genotoxins in a synthetic process are challenging because of GTIs' evolving nature and variable points of entry. Hence, synthetic routes should be screened for the identification of structural elements that cause genotoxicity. Based on EMA guidelines, the TTC value of GTIs is 1.5 μg/day, but the value varies according to daily dose and length of use. Bearing in mind the sensitivity requirements of respective impurities, the authors developed an analytical matrix using GC methods. The analytical methods described here fulfilled the regulatory guidelines.

V. Gangadhar* is an executive in the Analytical Research Department, Y. Pardha Saradhi is a manager in the Analytical Research Department, and R. Rajavikram is a project trainee, all at Neuland Laboratories, Temple St., Bonthapalli Village, Jinnaram Mandal, Medak District 502 313 (A.P.), India, tel. +91 08458 392629,
.

*To whom all correspondence should be addressed.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
18%
To all process for new products only
13%
To select process for new products only
22%
To select processes for both new and legacy products
22%
Do not use QbD
24%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here